markers in patients with small cell lung cancer,' 12 and one report suggests that CK-BB may be useful as a diagnostic aid in cases of occult tumour. '3 The neuropeptide bombesin, which occurs physiologically at low concentrations in many tissues, has been shown to be produced at high concentrations by small cell lung cancer cell lines.'4" Specific membrane receptors for bombesin and related peptides have been identified on small cell lung cancer cells '6 and there is good evidence that these substances can stimulate proliferation of small cell lung cancer cells, thereby acting as autocrine growth factors. Further proof of this function came from a study where a monoclonal antibody to bombesin was used to block its binding to receptors on small cell lung cancer cells." Inhibition of clonal growth in vitro and regression of xenografts in vivo were seen. This novel approach to manipulating the growth of small cell lung cancer cells may offer a more rational alternative to cytotoxic drugs in treating patients with small cell lung cancer. Clinical studies evaluating the use of bombesin antagonists or antireceptor antibodies in small cell lung cancer are eagerly awaited.
Cytogenetic studies
Continuous cell lines provide good specimens for conducting tumour cytogenetic analyses. Abnormali Over the past five years a wealth of information on the biology, biochemistry, and cytogenetics of human lung cancer has been generated by studies based on laboratory models. Much is now known about the specific growth requirements of lung cancer cells growing in vitro and the factors that regulate tumour cell proliferation. It is hoped that these advances in understanding can be translated into a form that would benefit patients with lung cancer. The development of newer, more effective treatment for patients with widespread disease is by far the most pressing need. 
